Interested in promotions? | Click here >>
8177
SP600125
Activators & Inhibitors
Chemical Modulators

SP600125 #8177

Reviews ()
Citations (0)
other Image 1 - SP600125

Chemical structure of SP600125.

other Image 2 - SP600125

Western blot analysis of extracts from 293T cells, untreated or treated with anisomycin (25 μg/ml) for the indicated times either with or without SP600125 pre-treatment (50 μM, 40 min), using Phospho-JunB (Thr102/Thr104) (D3C6) Rabbit mAb #8053 (upper) or JunB (C37F9) Rabbit mAb #3753 (lower).

other Image 3 - SP600125

Western blot analysis of extracts from 293T cells, untreated or treated with anisomycin (25 μg/ml, 15 min) either with or without SP600125 pre-treatment (50 μM, 40 min), using Phospho-c-Jun (Ser73) (D47G9) XP® Rabbit mAb #3270 (upper) or c-Jun (60A8) Rabbit mAb #9165 (lower).

Product Usage Information

SP600125 is supplied as a lyophilized powder. For a 25 mM stock, reconstitute the 10 mg in 1.82 ml DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used as a pre-treatment at 25-50 μM for 15-45 minutes prior to treating with a stimulator. Soluble in DMSO at 65 mg/ml; poorly soluble in ethanol and water.

Storage

Store lyophilized or in solution at -20ºC, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Product Description

Molecular Weight 220.23 g/mol
Purity

>99%

Molecular Formula

C14H8N2O

CAS 129-56-6
Solubility Soluble in DMSO at 65mg/ml.

Background

Novel, potent, and selective JNK-1,-2, and -3 inhibitor, SP600125 is an ATP-competetive inhibitor effective on a range of kinases and enzymes. In cells, SP600125 caused a dose-dependent inhibition of the phosphorylation of c-Jun, the expression of inflammatory genes IL-2, COX-2, TNF-α, IFN-γ, and blocked the activation and differentiation of primary human CD4 cell cultures (1). SP600125 has also demonstrated inhibitory effects on tumor cell proliferation, endothelial cell migration, and tumor growth as well as blocking tumor and endothelial cells in the G2 phase of the cell cycle (2).

  1. Bennett, B.L. et al. (2001) Proc Natl Acad Sci U S A 98, 13681-6.
  2. Ennis, B.W. et al. (2005) J Pharmacol Exp Ther 313, 325-32.
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
To Purchase # 8177S
Product # Size Price
8177S
10 mg $ 216